Utah sues J&J, AstraZeneca over antipsychotic marketing; Drugmakers agree to slice Aussie prices by A$2B;

 @FiercePharma: FDA probes prostate meds for diabetes, heart risks. Article | Follow @FiercePharma

> Live From BIO 2010: Hamburg discusses advancing regulatory science. Story

> Live from BIO: What do biotech VCs want? Report

> Utah's attorney general has sued Johnson & Johnson and AstraZeneca, alleging that they failed to disclose side effects, notably diabetes, caused by their antipsychotic drugs Risperdal and Seroquel. Report

> Pharmaceutical companies have agreed to cut the Australian government's medicine bill by A$2 billion over the next four years in return for certainty about pricing changes in future. Report

> Troubled drugmaker KV Pharmaceutical says an independent expert certified that its manufacturing systems were in compliance with federal regulations. Report

> Cephalon reported much-better-than-expected first-quarter earnings, helped by increased sales of its Treanda cancer drug and cost controls, and the company raised its full-year earnings forecast. Report

> King Pharmaceuticals posted first-quarter profit below analyst targets on Wednesday, as sales fell for its Skelaxin muscle relaxant and several other drugs. Report

> The U.S. still has 71 million doses of H1N1 swine flu vaccine that have not been used, but it is not yet time to throw them out, the federal government said on Monday. Report

> Bristol-Myers Squibb says its board authorized the repurchase of up to $3 billion of its common stock. Report

> Pakistan's largest branded generic pharmaceutical company, Getz Pharma, plans to invest over $45 million in Malaysia for R&D, production and commercialization of sterile injectables and other biopharmaceutical products. Report

> HCL Technologies, an Indian consulting firm with offices in Cary, has signed a five-year, $500 million deal with Merck that will create at least 100 jobs in the area. Report

> Mylan said it received FDA approval for a generic version of GlaxoSmithKline's smoking cessation treatment Zyban. Report

Biotech News

 @FierceBiotech: E&Y: 2009 forever changed the biopharma industry. Report |  Follow @FierceBiotech 

 @JohnCFierce: So much for playing the InterMune price game. That will have to wait awhile. | Follow @JohnCFierce

> Safety concerns force Glaxo to suspend enrollment in SRT501 trial. Item

> Venter Institute raises $53M in sale-leaseback deal. Story

> New licensing chiefs for AZ, Genentech talk deal strategy. Report

> Sanofi chops 70 jobs in Canada. Item

> Live from BIO 2010: Day two in review. Article

> Merck takes control of Ariad cancer program in $583M deal. News

Medical Device News

> Medtronic agrees to buy ATS Medical. Item

> Oxford Immunotec gets $26 million in Series D. Story

> FDA orders recall of Baxter pumps. News

> Landec acquires Lifecore Biomedical. Report

> Escalon divests vascular lines to Vascular Solutions. Story

Drug Delivery News

> Novo starts GLP-1 trial with Merrion tech. Story

> Healthcare of Today acquires Macuclear/dry AMD technology. Item

> Nanoparticle formulation of doxorubicin cancer treatment developed. Report

> Althea acquires Altus' assets, IP portfolio. News

And Finally... Smoking, dietary changes and sedentary lifestyles are stoking a surge in heart disease and stroke in China that will kill an additional 7.7 million people over the next two decades. Report